Novavax (NVAX) vs Xencor (XNCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Xencor (XNCR) has outperformed Novavax (NVAX) over the past year, gaining 88.6% versus a gain of 48.4%. Over five years, XNCR leads with a -36.0% price change compared with -92.1% for NVAX. Novavax is the larger company by market cap ($2.10 billion vs $1.83 billion), about 1.1 times the size.
Novavax converts more of its revenue into profit, with a net margin of 39.2% versus -73.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NVAX | XNCR |
|---|---|---|
| Share price | $12.75 | $24.63 |
| Market cap | $2.10B | $1.83B |
| 1-day change | +15.80% | +0.53% |
| YTD return | +89.73% | +60.88% |
| 1-year return | +48.43% | +88.59% |
| 5-year return | -92.13% | -35.98% |
| EPS (TTM) | $-1.83 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.12B | $125.58M |
| Revenue growth (YoY) | +64.69% | +13.65% |
| Net income (latest FY) | $440.30M | $-91.92M |
| Gross margin | 93.50% | — |
| Operating margin | 40.30% | -141.35% |
| Net margin | 39.19% | -73.20% |
| 52-week high | $13.39 | $30.61 |
| 52-week low | $6.20 | $10.38 |
| Distance from 52-week high | -4.78% | -19.54% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +9.80% | +27.57% |
| Average volume | 5.22M | 1.32M |
| Shares outstanding | 164.95M | 74.35M |
| Employees | 749 | 260 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XNCR has outperformed NVAX by 40.2 percentage points over the past year.
- Novavax is more profitable, keeping 39.2 cents of every revenue dollar as net income versus -73.2 cents for Xencor.
- Novavax grew revenue faster in its latest fiscal year (+64.69% vs +13.65%).
About Novavax
NVAX stock →Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 749 employees
About Xencor
XNCR stock →Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
NVAX vs XNCR FAQ
Which is bigger, Novavax or Xencor?
Novavax (NVAX) is larger, with a market capitalization of $2.10B compared with $1.83B for Xencor (XNCR).
Which stock has performed better over the past year, NVAX or XNCR?
XNCR returned +88.59% over the past 12 months, compared with +48.43% for NVAX (price return, excluding dividends). Past performance does not predict future results.
Are Novavax and Xencor in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Novavax and Biotechnology: Pharmaceutical Preparations for Xencor.